Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Dianthus Therapeutics Inc (NASDAQ: DNTH) was $34.46 for the day, down -1.37% from the previous closing price of $34.94. In other words, the price has decreased by -$1.37 from its previous closing price. On the day, 0.69 million shares were traded. DNTH stock price reached its highest trading level at $36.39 during the session, while it also had its lowest trading level at $33.96.
Ratios:
Our analysis of DNTH’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 13.12 and its Current Ratio is at 13.12. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 03, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $48.Oppenheimer initiated its Outperform rating on October 03, 2024, with a $48 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 09 ’25 when Savitz Ryan sold 20,000 shares for $35.00 per share. The transaction valued at 700,000 led to the insider holds 0 shares of the business.
RYAN SAVITZ bought 20,000 shares of DNTH for $636,000 on Sep 09 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNTH now has a Market Capitalization of 1372067072 and an Enterprise Value of 853151360. For the stock, the TTM Price-to-Sale (P/S) ratio is 282.90 while its Price-to-Book (P/B) ratio in mrq is 3.66. Its current Enterprise Value per Revenue stands at 175.763 whereas that against EBITDA is -6.572.
Stock Price History:
The Beta on a monthly basis for DNTH is 1.58, which has changed by 0.23115396 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, DNTH has reached a high of $40.16, while it has fallen to a 52-week low of $13.36. The 50-Day Moving Average of the stock is 21.26%, while the 200-Day Moving Average is calculated to be 53.30%.
Shares Statistics:
DNTH traded an average of 638.11K shares per day over the past three months and 678410 shares per day over the past ten days. A total of 32.18M shares are outstanding, with a floating share count of 29.04M. Insiders hold about 27.05% of the company’s shares, while institutions hold 86.24% stake in the company. Shares short for DNTH as of 1757894400 were 5123594 with a Short Ratio of 8.03, compared to 1755216000 on 5983909. Therefore, it implies a Short% of Shares Outstanding of 5123594 and a Short% of Float of 15.100000999999999.
Earnings Estimates
. The current rating of Dianthus Therapeutics Inc (DNTH) reflects the combined expertise of 6 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.87, with high estimates of -$0.75 and low estimates of -$1.09.
Analysts are recommending an EPS of between -$3.3 and -$3.83 for the fiscal current year, implying an average EPS of -$3.5. EPS for the following year is -$3.63, with 5.0 analysts recommending between -$3.05 and -$4.47.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for DNTH’s current fiscal year. The highest revenue estimate was $5.03M, while the lowest revenue estimate was $1.36M, resulting in an average revenue estimate of $2.52M. In the same quarter a year ago, actual revenue was $6.24M
